Dogwood Therapeutics Files 8-K/A Amendment
Ticker: DWTX · Form: 8-K/A · Filed: Dec 18, 2024 · CIK: 1818844
| Field | Detail |
|---|---|
| Company | Dogwood Therapeutics, INC. (DWTX) |
| Form Type | 8-K/A |
| Filed Date | Dec 18, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, financial-statements, exhibits
Related Tickers: DWTX
TL;DR
Dogwood Therapeutics (DWTX) filed an 8-K/A amendment on Dec 18, updating financial statements from Oct 4.
AI Summary
Dogwood Therapeutics, Inc. filed an 8-K/A amendment on December 18, 2024, related to events on October 4, 2024. The filing primarily concerns financial statements and exhibits, indicating a potential update or correction to previously filed information. The company, formerly known as Virios Therapeutics, Inc., is incorporated in Delaware and headquartered in Alpharetta, Georgia.
Why It Matters
This amendment to a previous filing suggests Dogwood Therapeutics is providing updated or corrected financial information, which could be significant for investors assessing the company's financial health.
Risk Assessment
Risk Level: medium — Amendments to SEC filings can indicate previously undisclosed issues or corrections, requiring closer investor scrutiny.
Key Players & Entities
- Dogwood Therapeutics, Inc. (company) — Registrant
- Virios Therapeutics, Inc. (company) — Former company name
- October 4, 2024 (date) — Earliest event date
- December 18, 2024 (date) — Filing date
- 8666208655 (phone_number) — Business phone number
- 44 Milton Avenue (address) — Principal executive offices
- Alpharetta, GA 30009 (address) — Principal executive offices
FAQ
What specific financial statements or exhibits are being amended by Dogwood Therapeutics?
The filing indicates that the amendment pertains to 'Financial Statements and Exhibits' but does not specify which particular statements or exhibits are being updated or corrected.
What was the original event date that this 8-K/A filing is amending?
The earliest event reported in this 8-K/A filing is October 4, 2024.
When was this 8-K/A amendment officially filed with the SEC?
This 8-K/A amendment was filed as of date December 18, 2024.
What is the former name of Dogwood Therapeutics, Inc.?
Dogwood Therapeutics, Inc. was formerly known as Virios Therapeutics, Inc. and Virios Therapeutics, LLC.
Where are Dogwood Therapeutics, Inc.'s principal executive offices located?
The principal executive offices of Dogwood Therapeutics, Inc. are located at 44 Milton Avenue, Alpharetta, GA 30009.
Filing Stats: 871 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2024-12-18 09:30:27
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 DWTX Nasdaq Capital Market Check t
Filing Documents
- dwtx-20241004x8ka.htm (8-K/A) — 48KB
- dwtx-20241004xex23d1.htm (EX-23.1) — 3KB
- dwtx-20241004xex99d1.htm (EX-99.1) — 438KB
- dwtx-20241004xex99d2.htm (EX-99.2) — 353KB
- dwtx-20241004xex99d3.htm (EX-99.3) — 346KB
- dwtx-20241004xex99d2001.jpg (GRAPHIC) — 3KB
- 0001558370-24-016346.txt ( ) — 1403KB
- dwtx-20241004.xsd (EX-101.SCH) — 3KB
- dwtx-20241004_lab.xml (EX-101.LAB) — 16KB
- dwtx-20241004_pre.xml (EX-101.PRE) — 10KB
- dwtx-20241004x8ka_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (a) Financial statements of businesses acquired. The audited financial statements and accompanying notes of Pharmagesic (Holdings) Inc. as of and for the years ended December 31, 2023 and 2022 are filed as Exhibit 99.1 to this Current Report on Form 8-K/A and incorporated herein by reference. The unaudited interim financial statements and accompanying notes of Pharmagesic (Holdings) Inc. as of and for the nine months ended September 30, 2024 and 2023 are filed as Exhibit 99.2 to this Current Report on Form 8-K/A and incorporated herein by reference. (b) Pro forma financial information. The unaudited pro forma condensed combined balance sheet as of September 30, 2024, the unaudited pro forma condensed combined statement of operation for the nine months ended September 30, 2024, the unaudited pro forma combined statement of operations for the year ended December 31, 2023, and the related notes of Dogwood Therapeutics, Inc. with respect to the transaction described above, are filed as Exhibit 99.3 to this Current Report on Form 8-K/A and incorporated herein by reference. (d) Exhibits . Exhibit Number Description 23.1 Consent of Deloitte Touche Tohmatsu, the independent auditor of Pharmagesic (Holdings) Inc. 99.1 Audited financial statements of Pharmagesic (Holdings) Inc., as of and for the years ended December 31, 2023 and 2022. 99.2 Unaudited interim financial statements of Pharmagesic (Holdings) Inc., as of and for the nine months ended September 30, 2024 and 2023. 99.3 Unaudited pro form condensed combined financial information of Dogwood Therapeutics, Inc., as of and for the nine months ended September 30, 2024, and for the year ended December 31, 2023. 104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DOGWOOD THERAPEUTICS, INC. By: /s/ Angela Walsh Name: Angela Walsh Title: Chief Financial Officer, Corporate Secretary and Treasurer December 18, 2024 3